Published in AIDS on October 01, 2008
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med (2011) 3.93
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther (2012) 3.16
Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis (2010) 1.55
Debating clinical utility. Public Health Genomics (2010) 1.41
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS (2012) 1.26
Clinically available pharmacogenomics tests. Clin Pharmacol Ther (2009) 1.13
Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol (2011) 1.09
The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend (2012) 1.01
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials (2010) 1.00
Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. J Allergy Clin Immunol Pract (2014) 0.96
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis (2012) 0.93
Genotyping for severe drug hypersensitivity. Curr Allergy Asthma Rep (2014) 0.92
HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr (2010) 0.89
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol (2011) 0.89
Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther (2012) 0.88
The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods. Curr Genomics (2012) 0.87
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials (2012) 0.84
Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res (2010) 0.83
New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol (2015) 0.80
Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe. J Pers Med (2015) 0.80
Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics (2015) 0.80
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. Int J Mol Sci (2016) 0.79
Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. PLoS One (2016) 0.79
Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing. Expert Rev Cardiovasc Ther (2010) 0.79
Role of pharmacogenetics in public health and clinical health care: a SWOT analysis. Eur J Hum Genet (2016) 0.79
Antiviral drug allergy. Immunol Allergy Clin North Am (2014) 0.76
Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities. Curr Opin HIV AIDS (2015) 0.76
Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients. Tanaffos (2016) 0.75
The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done? Clin Pharmacol Ther (2015) 0.75
MinION: A Novel Tool for Predicting Drug Hypersensitivity? Front Pharmacol (2016) 0.75
Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany. Adv Ther (2016) 0.75
Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality. J Public Health Africa (2013) 0.75
Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies. Pharmacogenomics J (2016) 0.75
Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J (2017) 0.75
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 5.48
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet (2002) 3.84
Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics (2004) 2.88
Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS (2001) 2.65
Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA (2001) 2.49
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis (2006) 2.40
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr (2006) 2.17
The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol (2006) 2.10
Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther (2001) 1.93
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr (2006) 1.76
Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr (2007) 1.20
Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis (2006) 0.97
Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scand J Infect Dis (2007) 0.88
Questionable history of immediate-type hypersensitivity to penicillin in Staphylococcal endocarditis: treatment based on skin-test results vers-us empirical alternative treatment--A decision analysis. Clin Infect Dis (1999) 0.88
Cost-effectiveness of the pneumococcal vaccine in healthy younger adults. Med Decis Making (2002) 0.87
Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. Drug Saf (2006) 0.84
Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics (2007) 0.82
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med (2011) 4.21
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med (2004) 2.92
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med (2008) 2.74
Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am (2005) 2.67
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis (2006) 2.45
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis (2012) 2.38
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med (2011) 2.35
HIV/AIDS, undernutrition, and food insecurity. Clin Infect Dis (2009) 2.33
Alcohol consumption and HIV disease progression: are they related? Alcohol Clin Exp Res (2003) 2.32
Identifying undiagnosed human immunodeficiency virus: the yield of routine, voluntary inpatient testing. Arch Intern Med (2002) 2.30
Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J (2008) 2.30
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr (2009) 2.24
HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther (2009) 2.18